Feb. 18, 2022 |
|
Dec. 20, 2023 |
|
jRCTs051210176 |
A double-blind, randomized placebo-controlled study evaluating the effect of highly bioavailable curcumin on prevention of disesase progression in coronavirus disease 2019 (COVID-19) patients with no symptoms. (Curcu-COVID study) |
|
Highly bioavailable curcumin in COVID-19 with no symptoms. (Curcu-COVID study) |
Hasegawa Koji |
||
National Hospital Organization Kyoto Medical Center |
||
1-1 Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto, Kyoto |
||
+81-75-641-9161 |
||
koj@kuhp.kyoto-u.ac.jp |
||
Hasegawa Koji |
||
National Hospital Organization Kyoto Medical Center |
||
1-1 Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto, Kyoto |
||
+81-75-641-9161 |
||
koj@kuhp.kyoto-u.ac.jp |
Not Recruiting |
Feb. 18, 2022 |
||
160 | ||
Interventional |
||
randomized controlled trial |
||
double blind |
||
placebo control |
||
parallel assignment |
||
prevention purpose |
||
(1) Within 5 days after being diagnosed as COVID-19 by PCR test or antigen test (described in the guideline for medical treatment of COVID-19, 5.3 th edition (Ministry of Health, Labor and Welfare)). |
||
(1) Patients taking antithrombotic drugs (anticoagulants, EPA preparations, prostacyclin preparations) |
||
20age old over | ||
No limit | ||
Both |
||
Coronavirus infection (COVID-19) |
||
Arm highly bioavailable curcumin : curcuRougeTM (90mg/capsule), 4 capsules are given twice a day. (8 capsules/day, morning and evening) for 7 days. |
||
Coronavirus infection (COVID-19) |
||
Combination of the following events |
||
Each of the following events |
Therabiopharma Inc. | |
Not applicable |
Therabiopharma Inc. | |
Not applicable |
Nara Medical University Certified Review Board | |
840 Shijo-Cho, Kashihara, Nara | |
+81-744-29-8835 |
|
ethics_nara@naramed-u.ac.jp | |
Approval | |
none |